Augmentation of the anti-lymphoma activity of an anti-CD19 immunotoxin by anti-CD20 antibody is mediated via a complement-dependent mechanism.

被引：0
|
作者：
Flavell, DJ [1 ]
Warnes, SL [1 ]
Symons, M [1 ]
Noss, A [1 ]
Flavell, SU [1 ]
机构：
[1] Univ Southampton, Sch Med, Simon Flavell Leukemia Res Unit, Southampton, Hants, England
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1475
引用
收藏
页码：342A / 342A
页数：1
相关论文
共 50 条
  • [1] THE ANTITUMOR-ACTIVITY OF AN ANTI-CD22 IMMUNOTOXIN IN SCID MICE WITH DISSEMINATED DAUDI LYMPHOMA IS ENHANCED BY EITHER AN ANTI-CD19 ANTIBODY OR AN ANTI-CD19 IMMUNOTOXIN
    GHETIE, MA
    TUCKER, K
    RICHARDSON, J
    UHR, JW
    VITETTA, ES
    BLOOD, 1992, 80 (09) : 2315 - 2320
  • [2] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20
    Goldenberg, DM
    On, ZX
    Horak, ID
    Hansen, H
    Stein, R
    FASEB JOURNAL, 2003, 17 (07): : C123 - C123
  • [3] Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Dalle, Stephane
    Reslan, Lina
    de Horts, Timothee Besseyre
    Herveau, Stephanie
    Herting, Frank
    Plesa, Adriana
    Friess, Thomas
    Umana, Pablo
    Klein, Christian
    Dumontet, Charles
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (01) : 178 - 185
  • [4] Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity
    Lv, Ming
    Lin, Zhou
    Qiao, Chunxia
    Gen, Shusheng
    Lang, Xiaoling
    Li, Yan
    Feng, Jiannan
    Shen, Beifen
    CANCER LETTERS, 2010, 294 (01) : 66 - 73
  • [5] The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma
    Flavell, DJ
    Warnes, SL
    Bryson, CJ
    Field, SA
    Noss, AL
    Packham, G
    Flavell, SU
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (02) : 157 - 170
  • [6] Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity
    Natsume, Akito
    Shimizu-Yokoyama, Yukiko
    Satoh, Mitsuo
    Shitara, Kenya
    Niwa, Rinpei
    CANCER SCIENCE, 2009, 100 (12): : 2411 - 2418
  • [7] Acquisition of complement-dependent cytotoxicity by type II anti-CD20 therapeutic antibody obinutuzumab
    Kuzniewska, Alicja
    Majeranowski, Alan
    Kowalska, Daria
    Urban, Aleksandra
    Henry, Sara
    Okroj, Marcin
    MOLECULAR IMMUNOLOGY, 2022, 141 : 122 - 123
  • [8] The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
    Kuzniewska, Alicja
    Majeranowski, Alan
    Henry, Sara
    Kowalska, Daria
    Stasilojc, Grzegorz
    Urban, Aleksandra
    Zaucha, Jan M.
    Okroj, Marcin
    CANCERS, 2024, 16 (01)
  • [9] A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
    GazzanoSantoro, H
    Ralph, P
    Ryskamp, TC
    Chen, AB
    Mukku, VR
    JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 202 (02) : 163 - 171
  • [10] Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
    Kohrt, Holbrook E.
    Thielens, Ariane
    Marabelle, Aurelien
    Sagiv-Barfi, Idit
    Sola, Caroline
    Chanuc, Fabien
    Fuseri, Nicolas
    Bonnafous, Cecile
    Czerwinski, Debra
    Rajapaksa, Amanda
    Waller, Erin
    Ugolini, Sophie
    Vivier, Eric
    Romagne, Francois
    Levy, Ronald
    Blery, Mathieu
    Andre, Pascale
    BLOOD, 2014, 123 (05) : 678 - 686
12345